Lytgobi
Lytgobi ingredients
| Active ingredient | Strength |
|---|---|
| Futibatinib | 4 mg/1, 16 mg/1 |
What Lytgobi is used for
The FDA lists the approved uses on the official label (below). In the EU, futibatinib is approved as Lytgobi for:
Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Lytgobi
- Generic name
- Futibatinib
- Made by
- TAIHO PHARMACEUTICAL CO., LTD.
- Forms
- Tablet
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA214801
- On the US market since
- 2023
Official information
- Lytgobi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Futibatinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lytgobi?
Lytgobi (Futibatinib) is a cancer medicine made by TAIHO PHARMACEUTICAL CO., LTD., approved by the US FDA.
What are the ingredients of Lytgobi?
Lytgobi contains Futibatinib (4 mg/1, 16 mg/1).
Is Lytgobi approved in Europe?
The same active substance is approved in the EU as Lytgobi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA